Total Funding
65
58
Total FundingGrant raised
Growth Score
-1 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
137044
Adivo is a veterinary biotechnology company .
Lena Krzyzak: Investor- Kathrin Ladetzki-Baehs: Founder & Managing DirectorPast Role: MorphoSys, Associate Director & Director
About the Company
adivo is a veterinary biotechnology company developing therapeutic antibodies for pets. The focus is on the treatment of serious diseases in dogs with the potential to offer therapies for other species as well. The antibody selection is based on a new, fully synthetic, dog-specific drug library that can be used to isolate antibodies with optimal
properties using phage display technology. adivo is a spin-off of MorphoSys AG. Many years of expertise in the development of human therapeutic antibodies transfer the adivo team into veterinary medicine.
